Skip to main content
Erschienen in: Clinical Research in Cardiology 12/2017

04.08.2017 | Original Paper

Biological variation of extracellular matrix biomarkers in patients with stable chronic heart failure

Erschienen in: Clinical Research in Cardiology | Ausgabe 12/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Extracellular matrix (ECM) biomarkers such as matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) are pathophysiological key, prognostic marker and therapeutic target in chronic heart failure (HF). Serial measurements of MMPs and TIMPs may be useful for guidance of these applications. However, interpretation of time-dependent changes requires knowledge about the biological variation of ECM biomarkers.

Methods

We performed measurements of MMP-2, MMP-9, TIMP-1, and TIMP-4 in 50 patients with chronic HF who met rigid criteria for clinical stability at 3-h, 6-h, 1-week and 2-week time intervals. In addition, clinical and haemodynamic assessment was performed at baseline, at 1- and 2-week intervals. Haemodynamic variables were measured using inert gas rebreathing and impedance cardiography. Heart rhythm was monitored with external ECG event recorders throughout the complete study. Reference change values (RCVs) and minimal important differences (MIDs) were determined for MMP-2, MMP-9, TIMP-1, and TIMP-4.

Results

Clinical and haemodynamic variables were stable over time. Depending on the time-interval, RCVs ranged between 4.9 and 11.7% for MMP-2, 26.4 and 56.7% for MMP-9, 10.8 and 30.7% for TIMP-1, and 16.0 and 47.4% for TIMP-4, respectively. The MIDs varied between 43.38 and 65.22 ng/ml for MMP-2, 28.71 and 40.96 ng/ml for MMP-9, 52.32 and 156.07 ng/ml for TIMP-1, and 293.92 and 798.04 pg/ml for TIMP-4, respectively.

Conclusion

The biological variation of ECM biomarkers differs with respect to individual biomarkers and time intervals. MMP-2 may be most suitable for serial biomarker measurements, as the biological variation is low irrespective of the time interval between measurements.
Literatur
1.
Zurück zum Zitat Li YY, McTiernan CF, Feldman AM (2000) Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 46(2):214–224CrossRefPubMed Li YY, McTiernan CF, Feldman AM (2000) Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 46(2):214–224CrossRefPubMed
2.
Zurück zum Zitat Mukherjee R, Herron AR, Lowry AS, Stroud RE, Stroud MR, Wharton JM, Ikonomidis JS, Crumbley AJ 3rd, Spinale FG, Gold MR (2006) Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol 97(4):532–537. doi:10.1016/j.amjcard.2005.08.073 CrossRefPubMed Mukherjee R, Herron AR, Lowry AS, Stroud RE, Stroud MR, Wharton JM, Ikonomidis JS, Crumbley AJ 3rd, Spinale FG, Gold MR (2006) Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol 97(4):532–537. doi:10.​1016/​j.​amjcard.​2005.​08.​073 CrossRefPubMed
3.
Zurück zum Zitat Diez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Martinez Ubago JL (2002) Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105(21):2512–2517CrossRefPubMed Diez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Martinez Ubago JL (2002) Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105(21):2512–2517CrossRefPubMed
4.
Zurück zum Zitat Izawa H, Murohara T, Nagata K, Isobe S, Asano H, Amano T, Ichihara S, Kato T, Ohshima S, Murase Y, Iino S, Obata K, Noda A, Okumura K, Yokota M (2005) Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation 112(19):2940–2945. doi:10.1161/circulationaha.105.571653 PubMed Izawa H, Murohara T, Nagata K, Isobe S, Asano H, Amano T, Ichihara S, Kato T, Ohshima S, Murase Y, Iino S, Obata K, Noda A, Okumura K, Yokota M (2005) Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation 112(19):2940–2945. doi:10.​1161/​circulationaha.​105.​571653 PubMed
5.
Zurück zum Zitat Heymans S, Schroen B, Vermeersch P, Milting H, Gao F, Kassner A, Gillijns H, Herijgers P, Flameng W, Carmeliet P, Van de Werf F, Pinto YM, Janssens S (2005) Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation 112(8):1136–1144. doi:10.1161/CIRCULATIONAHA.104.516963 CrossRefPubMed Heymans S, Schroen B, Vermeersch P, Milting H, Gao F, Kassner A, Gillijns H, Herijgers P, Flameng W, Carmeliet P, Van de Werf F, Pinto YM, Janssens S (2005) Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation 112(8):1136–1144. doi:10.​1161/​CIRCULATIONAHA.​104.​516963 CrossRefPubMed
6.
Zurück zum Zitat Manhenke C, Ueland T, Jugdutt BI, Godang K, Aukrust P, Dickstein K, Orn S (2014) The relationship between markers of extracellular cardiac matrix turnover: infarct healing and left ventricular remodelling following primary PCI in patients with first-time STEMI. Eur Heart J 35(6):395–402. doi:10.1093/eurheartj/eht482 CrossRefPubMed Manhenke C, Ueland T, Jugdutt BI, Godang K, Aukrust P, Dickstein K, Orn S (2014) The relationship between markers of extracellular cardiac matrix turnover: infarct healing and left ventricular remodelling following primary PCI in patients with first-time STEMI. Eur Heart J 35(6):395–402. doi:10.​1093/​eurheartj/​eht482 CrossRefPubMed
8.
Zurück zum Zitat George J, Patal S, Wexler D, Roth A, Sheps D, Keren G (2005) Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am Heart J 150(3):484–487. doi:10.1016/j.ahj.2004.11.016 CrossRefPubMed George J, Patal S, Wexler D, Roth A, Sheps D, Keren G (2005) Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am Heart J 150(3):484–487. doi:10.​1016/​j.​ahj.​2004.​11.​016 CrossRefPubMed
9.
Zurück zum Zitat Radauceanu A, Ducki C, Virion JM, Rossignol P, Mallat Z, McMurray J, Van Veldhuisen DJ, Tavazzi L, Mann DL, Capiaumont-Vin J, Li M, Hanriot D, Zannad F (2008) Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure. J Card Fail 14(6):467–474. doi:10.1016/j.cardfail.2008.02.014 CrossRefPubMed Radauceanu A, Ducki C, Virion JM, Rossignol P, Mallat Z, McMurray J, Van Veldhuisen DJ, Tavazzi L, Mann DL, Capiaumont-Vin J, Li M, Hanriot D, Zannad F (2008) Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure. J Card Fail 14(6):467–474. doi:10.​1016/​j.​cardfail.​2008.​02.​014 CrossRefPubMed
11.
Zurück zum Zitat Wilson EM, Gunasinghe HR, Coker ML, Sprunger P, Lee-Jackson D, Bozkurt B, Deswal A, Mann DL, Spinale FG (2002) Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail 8(6):390–398. doi:10.1054/jcaf.2002.129659 CrossRefPubMed Wilson EM, Gunasinghe HR, Coker ML, Sprunger P, Lee-Jackson D, Bozkurt B, Deswal A, Mann DL, Spinale FG (2002) Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail 8(6):390–398. doi:10.​1054/​jcaf.​2002.​129659 CrossRefPubMed
12.
Zurück zum Zitat Deardorff R, Spinale FG (2009) Cytokines and matrix metalloproteinases as potential biomarkers in chronic heart failure. Biomark Med 3(5):513–523CrossRefPubMedPubMedCentral Deardorff R, Spinale FG (2009) Cytokines and matrix metalloproteinases as potential biomarkers in chronic heart failure. Biomark Med 3(5):513–523CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Collier P, Watson CJ, Voon V, Phelan D, Jan A, Mak G, Martos R, Baugh JA, Ledwidge MT, McDonald KM (2011) Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? Eur J Heart Fail 13(10):1087–1095. doi:10.1093/eurjhf/hfr079 CrossRefPubMed Collier P, Watson CJ, Voon V, Phelan D, Jan A, Mak G, Martos R, Baugh JA, Ledwidge MT, McDonald KM (2011) Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? Eur J Heart Fail 13(10):1087–1095. doi:10.​1093/​eurjhf/​hfr079 CrossRefPubMed
15.
Zurück zum Zitat Plaksej R, Kosmala W, Frantz S, Herrmann S, Niemann M, Stork S, Wachter R, Angermann CE, Ertl G, Bijnens B, Weidemann F (2009) Relation of circulating markers of fibrosis and progression of left and right ventricular dysfunction in hypertensive patients with heart failure. J Hypertens 27(12):2483–2491. doi:10.1097/HJH.0b013e3283316c4d CrossRefPubMed Plaksej R, Kosmala W, Frantz S, Herrmann S, Niemann M, Stork S, Wachter R, Angermann CE, Ertl G, Bijnens B, Weidemann F (2009) Relation of circulating markers of fibrosis and progression of left and right ventricular dysfunction in hypertensive patients with heart failure. J Hypertens 27(12):2483–2491. doi:10.​1097/​HJH.​0b013e3283316c4d​ CrossRefPubMed
16.
Zurück zum Zitat Koskivirta I, Rahkonen O, Mayranpaa M, Pakkanen S, Husheem M, Sainio A, Hakovirta H, Laine J, Jokinen E, Vuorio E, Kovanen P, Jarvelainen H (2006) Tissue inhibitor of metalloproteinases 4 (TIMP4) is involved in inflammatory processes of human cardiovascular pathology. Histochem Cell Biol 126(3):335–342. doi:10.1007/s00418-006-0163-8 CrossRefPubMed Koskivirta I, Rahkonen O, Mayranpaa M, Pakkanen S, Husheem M, Sainio A, Hakovirta H, Laine J, Jokinen E, Vuorio E, Kovanen P, Jarvelainen H (2006) Tissue inhibitor of metalloproteinases 4 (TIMP4) is involved in inflammatory processes of human cardiovascular pathology. Histochem Cell Biol 126(3):335–342. doi:10.​1007/​s00418-006-0163-8 CrossRefPubMed
17.
Zurück zum Zitat Schumann C, Lepper PM, Frank H, Schneiderbauer R, Wibmer T, Kropf C, Stoiber KM, Rudiger S, Kruska L, Krahn T, Kramer F (2010) Circulating biomarkers of tissue remodelling in pulmonary hypertension. Biomarkers 15(6):523–532. doi:10.3109/1354750X.2010.492431 CrossRefPubMed Schumann C, Lepper PM, Frank H, Schneiderbauer R, Wibmer T, Kropf C, Stoiber KM, Rudiger S, Kruska L, Krahn T, Kramer F (2010) Circulating biomarkers of tissue remodelling in pulmonary hypertension. Biomarkers 15(6):523–532. doi:10.​3109/​1354750X.​2010.​492431 CrossRefPubMed
18.
Zurück zum Zitat Dini FL, Buralli S, Bajraktari G, Elezi S, Duranti E, Metelli MR, Carpi A, Taddei S (2010) Plasma matrix metalloproteinase-9 better predicts outcome than N-terminal protype-B natriuretic peptide in patients with systolic heart failure and a high prevalence of coronary artery disease. Biomed Pharmacother 64(5):339–342. doi:10.1016/j.biopha.2009.09.008 CrossRefPubMed Dini FL, Buralli S, Bajraktari G, Elezi S, Duranti E, Metelli MR, Carpi A, Taddei S (2010) Plasma matrix metalloproteinase-9 better predicts outcome than N-terminal protype-B natriuretic peptide in patients with systolic heart failure and a high prevalence of coronary artery disease. Biomed Pharmacother 64(5):339–342. doi:10.​1016/​j.​biopha.​2009.​09.​008 CrossRefPubMed
19.
Zurück zum Zitat Hopps E, Caimi G (2015) Matrix metalloproteases as a pharmacological target in cardiovascular diseases. Eur Rev Med Pharmacol Sci 19(14):2583–2589PubMed Hopps E, Caimi G (2015) Matrix metalloproteases as a pharmacological target in cardiovascular diseases. Eur Rev Med Pharmacol Sci 19(14):2583–2589PubMed
21.
Zurück zum Zitat Weir RA, Mark PB, Petrie CJ, Clements S, Steedman T, Ford I, Ng LL, Squire IB, Wagner GS, McMurray JJ, Dargie HJ (2009) Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect? Am Heart J 157(6):1088–1096. doi:10.1016/j.ahj.2009.04.001 CrossRefPubMed Weir RA, Mark PB, Petrie CJ, Clements S, Steedman T, Ford I, Ng LL, Squire IB, Wagner GS, McMurray JJ, Dargie HJ (2009) Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect? Am Heart J 157(6):1088–1096. doi:10.​1016/​j.​ahj.​2009.​04.​001 CrossRefPubMed
22.
Zurück zum Zitat Ferreira JP, Santos M, Oliveira JC, Marques I, Bettencourt P, Carvalho H (2015) Influence of spironolactone on matrix metalloproteinase-2 in acute decompensated heart failure. Arq Bras Cardiol 104(4):308–314. doi:10.5935/abc.20140205 PubMedPubMedCentral Ferreira JP, Santos M, Oliveira JC, Marques I, Bettencourt P, Carvalho H (2015) Influence of spironolactone on matrix metalloproteinase-2 in acute decompensated heart failure. Arq Bras Cardiol 104(4):308–314. doi:10.​5935/​abc.​20140205 PubMedPubMedCentral
23.
Zurück zum Zitat Li MJ, Huang CX, Okello E, Yanhong T, Mohamed S (2009) Treatment with spironolactone for 24 weeks decreases the level of matrix metalloproteinases and improves cardiac function in patients with chronic heart failure of ischemic etiology. Can J Cardiol 25(9):523–526CrossRefPubMedPubMedCentral Li MJ, Huang CX, Okello E, Yanhong T, Mohamed S (2009) Treatment with spironolactone for 24 weeks decreases the level of matrix metalloproteinases and improves cardiac function in patients with chronic heart failure of ischemic etiology. Can J Cardiol 25(9):523–526CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Fukui M, Goda A, Komamura K, Nakabo A, Masaki M, Yoshida C, Hirotani S, Lee-Kawabata M, Tsujino T, Mano T, Masuyama T (2016) Changes in collagen metabolism account for ventricular functional recovery following beta-blocker therapy in patients with chronic heart failure. Heart Vessels 31(2):173–182. doi:10.1007/s00380-014-0597-1 CrossRefPubMed Fukui M, Goda A, Komamura K, Nakabo A, Masaki M, Yoshida C, Hirotani S, Lee-Kawabata M, Tsujino T, Mano T, Masuyama T (2016) Changes in collagen metabolism account for ventricular functional recovery following beta-blocker therapy in patients with chronic heart failure. Heart Vessels 31(2):173–182. doi:10.​1007/​s00380-014-0597-1 CrossRefPubMed
25.
Zurück zum Zitat Zile MR, Jhund PS, Baicu CF, Claggett BL, Pieske B, Voors AA, Prescott MF, Shi V, Lefkowitz M, McMurray JJ, Solomon SD, Prospective Comparison of AWARBoMoHFWPEFI (2016) Plasma biomarkers reflecting profibrotic processes in heart failure with a preserved ejection fraction: data from the prospective comparison of ARNI With ARB on management of heart failure with preserved ejection fraction study. Circ Heart Fail 9(1):e002551. doi:10.1161/CIRCHEARTFAILURE.115.002551 CrossRefPubMedPubMedCentral Zile MR, Jhund PS, Baicu CF, Claggett BL, Pieske B, Voors AA, Prescott MF, Shi V, Lefkowitz M, McMurray JJ, Solomon SD, Prospective Comparison of AWARBoMoHFWPEFI (2016) Plasma biomarkers reflecting profibrotic processes in heart failure with a preserved ejection fraction: data from the prospective comparison of ARNI With ARB on management of heart failure with preserved ejection fraction study. Circ Heart Fail 9(1):e002551. doi:10.​1161/​CIRCHEARTFAILURE​.​115.​002551 CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Spinale FG, Coker ML, Krombach SR, Mukherjee R, Hallak H, Houck WV, Clair MJ, Kribbs SB, Johnson LL, Peterson JT, Zile MR (1999) Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function. Circ Res 85(4):364–376CrossRefPubMed Spinale FG, Coker ML, Krombach SR, Mukherjee R, Hallak H, Houck WV, Clair MJ, Kribbs SB, Johnson LL, Peterson JT, Zile MR (1999) Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function. Circ Res 85(4):364–376CrossRefPubMed
27.
Zurück zum Zitat Shirakabe A, Asai K, Hata N, Yokoyama S, Shinada T, Kobayashi N, Mizuno K (2010) Clinical significance of matrix metalloproteinase (MMP)-2 in patients with acute heart failure. Int Heart J 51(6):404–410CrossRefPubMed Shirakabe A, Asai K, Hata N, Yokoyama S, Shinada T, Kobayashi N, Mizuno K (2010) Clinical significance of matrix metalloproteinase (MMP)-2 in patients with acute heart failure. Int Heart J 51(6):404–410CrossRefPubMed
28.
Zurück zum Zitat Naito Y, Tsujino T, Lee-Kawabata M, Matsumoto M, Ezumi A, Nakao S, Goda A, Ohyanagi M, Masuyama T (2009) Matrix metalloproteinase-1 and -2 levels are differently regulated in acute exacerbation of heart failure in patients with and without left ventricular systolic dysfunction. Heart Vessels 24(3):181–186. doi:10.1007/s00380-008-1100-7 CrossRefPubMed Naito Y, Tsujino T, Lee-Kawabata M, Matsumoto M, Ezumi A, Nakao S, Goda A, Ohyanagi M, Masuyama T (2009) Matrix metalloproteinase-1 and -2 levels are differently regulated in acute exacerbation of heart failure in patients with and without left ventricular systolic dysfunction. Heart Vessels 24(3):181–186. doi:10.​1007/​s00380-008-1100-7 CrossRefPubMed
29.
Zurück zum Zitat Kampourides N, Tziakas D, Chalikias G, Papazoglou D, Maltezos E, Symeonides D, Konstantinides S (2012) Usefulness of matrix metalloproteinase-9 plasma levels to identify patients with preserved left ventricular systolic function after acute myocardial infarction who could benefit from eplerenone. Am J Cardiol 110(8):1085–1091. doi:10.1016/j.amjcard.2012.05.049 CrossRefPubMed Kampourides N, Tziakas D, Chalikias G, Papazoglou D, Maltezos E, Symeonides D, Konstantinides S (2012) Usefulness of matrix metalloproteinase-9 plasma levels to identify patients with preserved left ventricular systolic function after acute myocardial infarction who could benefit from eplerenone. Am J Cardiol 110(8):1085–1091. doi:10.​1016/​j.​amjcard.​2012.​05.​049 CrossRefPubMed
30.
Zurück zum Zitat Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, Guidelines ESCCfP (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29(19):2388–2442. doi:10.1093/eurheartj/ehn309 CrossRefPubMed Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, Guidelines ESCCfP (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29(19):2388–2442. doi:10.​1093/​eurheartj/​ehn309 CrossRefPubMed
31.
Zurück zum Zitat Tager T, Frohlich H, Franke J, Slottje K, Horsch A, Zdunek D, Hess G, Dosch A, Katus HA, Wians FH, Frankenstein L (2015) Biological variation of the cardiac index in patients with stable chronic heart failure: inert gas rebreathing compared with impedance cardiography. ESC Heart Fail 2(3):112–120. doi:10.1002/ehf2.12040 CrossRefPubMedPubMedCentral Tager T, Frohlich H, Franke J, Slottje K, Horsch A, Zdunek D, Hess G, Dosch A, Katus HA, Wians FH, Frankenstein L (2015) Biological variation of the cardiac index in patients with stable chronic heart failure: inert gas rebreathing compared with impedance cardiography. ESC Heart Fail 2(3):112–120. doi:10.​1002/​ehf2.​12040 CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130(6):461–470CrossRefPubMed Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130(6):461–470CrossRefPubMed
37.
Zurück zum Zitat Wyrwich KW, Tierney WM, Wolinsky FD (1999) Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 52(9):861–873CrossRefPubMed Wyrwich KW, Tierney WM, Wolinsky FD (1999) Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 52(9):861–873CrossRefPubMed
38.
Zurück zum Zitat Wells G, Beaton D, Shea B, Boers M, Simon L, Strand V, Brooks P, Tugwell P (2001) Minimal clinically important differences: review of methods. J Rheumatol 28(2):406–412PubMed Wells G, Beaton D, Shea B, Boers M, Simon L, Strand V, Brooks P, Tugwell P (2001) Minimal clinically important differences: review of methods. J Rheumatol 28(2):406–412PubMed
39.
Zurück zum Zitat Fraser C (2001) Changes in serial results. Biological variation: from principles to practice. AACC Press, Washington, pp 67–90 Fraser C (2001) Changes in serial results. Biological variation: from principles to practice. AACC Press, Washington, pp 67–90
40.
Zurück zum Zitat Frederiksen CB, Lomholt AF, Lottenburger T, Davis GJ, Dowell BL, Blankenstein MA, Christensen IJ, Brunner N, Nielsen HJ (2008) Assessment of the biological variation of plasma tissue inhibitor of metalloproteinases-1. Int J Biol Markers 23(1):42–47CrossRefPubMed Frederiksen CB, Lomholt AF, Lottenburger T, Davis GJ, Dowell BL, Blankenstein MA, Christensen IJ, Brunner N, Nielsen HJ (2008) Assessment of the biological variation of plasma tissue inhibitor of metalloproteinases-1. Int J Biol Markers 23(1):42–47CrossRefPubMed
41.
Zurück zum Zitat Engelberger RP, Limacher A, Kucher N, Baumann F, Silbernagel G, Benghozi R, Do DD, Willenberg T, Baumgartner I (2015) Biological variation of established and novel biomarkers for atherosclerosis: results from a prospective, parallel-group cohort study. Clin Chim Acta 447:16–22. doi:10.1016/j.cca.2015.05.003 CrossRefPubMed Engelberger RP, Limacher A, Kucher N, Baumann F, Silbernagel G, Benghozi R, Do DD, Willenberg T, Baumgartner I (2015) Biological variation of established and novel biomarkers for atherosclerosis: results from a prospective, parallel-group cohort study. Clin Chim Acta 447:16–22. doi:10.​1016/​j.​cca.​2015.​05.​003 CrossRefPubMed
42.
Zurück zum Zitat Ricós CPC, Minchinela J, Álvarez V, Simón M, Biosca C, Doménech M, Fernández P, Jiménez CV, Garcia-Lario JV, Cava F (2009) Application of biological variation—a review. Biochem Med 19(3):250–259. doi:10.11613/BM.2009.023 CrossRef Ricós CPC, Minchinela J, Álvarez V, Simón M, Biosca C, Doménech M, Fernández P, Jiménez CV, Garcia-Lario JV, Cava F (2009) Application of biological variation—a review. Biochem Med 19(3):250–259. doi:10.​11613/​BM.​2009.​023 CrossRef
44.
45.
Zurück zum Zitat Agostoni P, Cattadori G, Apostolo A, Contini M, Palermo P, Marenzi G, Wasserman K (2005) Noninvasive measurement of cardiac output during exercise by inert gas rebreathing technique: a new tool for heart failure evaluation. J Am Coll Cardiol 46(9):1779–1781. doi:10.1016/j.jacc.2005.08.005 CrossRefPubMed Agostoni P, Cattadori G, Apostolo A, Contini M, Palermo P, Marenzi G, Wasserman K (2005) Noninvasive measurement of cardiac output during exercise by inert gas rebreathing technique: a new tool for heart failure evaluation. J Am Coll Cardiol 46(9):1779–1781. doi:10.​1016/​j.​jacc.​2005.​08.​005 CrossRefPubMed
46.
Zurück zum Zitat Koobi T, Kaukinen S, Ahola T, Turjanmaa VM (1997) Non-invasive measurement of cardiac output: whole-body impedance cardiography in simultaneous comparison with thermodilution and direct oxygen Fick methods. Intensive Care Med 23(11):1132–1137CrossRefPubMed Koobi T, Kaukinen S, Ahola T, Turjanmaa VM (1997) Non-invasive measurement of cardiac output: whole-body impedance cardiography in simultaneous comparison with thermodilution and direct oxygen Fick methods. Intensive Care Med 23(11):1132–1137CrossRefPubMed
47.
Zurück zum Zitat Sobanski P, Sinkiewicz W, Kubica J, Blazejewski J, Bujak R (2008) The reliability of noninvasive cardiac output measurement using the inert gas rebreathing method in patients with advanced heart failure. Cardiol J 15(1):63–70PubMed Sobanski P, Sinkiewicz W, Kubica J, Blazejewski J, Bujak R (2008) The reliability of noninvasive cardiac output measurement using the inert gas rebreathing method in patients with advanced heart failure. Cardiol J 15(1):63–70PubMed
48.
Zurück zum Zitat Trinkmann F, Berger M, Hoffmann U, Borggrefe M, Kaden JJ, Saur J (2011) A comparative evaluation of electrical velocimetry and inert gas rebreathing for the non-invasive assessment of cardiac output. Clin Res Cardiol 100(10):935–943. doi:10.1007/s00392-011-0329-9 CrossRefPubMed Trinkmann F, Berger M, Hoffmann U, Borggrefe M, Kaden JJ, Saur J (2011) A comparative evaluation of electrical velocimetry and inert gas rebreathing for the non-invasive assessment of cardiac output. Clin Res Cardiol 100(10):935–943. doi:10.​1007/​s00392-011-0329-9 CrossRefPubMed
49.
Zurück zum Zitat Saur J, Fluechter S, Trinkmann F, Papavassiliu T, Schoenberg S, Weissmann J, Haghi D, Borggrefe M, Kaden JJ (2009) Noninvasive determination of cardiac output by the inert-gas-rebreathing method—comparison with cardiovascular magnetic resonance imaging. Cardiology 114(4):247–254. doi:10.1159/000232407 CrossRefPubMed Saur J, Fluechter S, Trinkmann F, Papavassiliu T, Schoenberg S, Weissmann J, Haghi D, Borggrefe M, Kaden JJ (2009) Noninvasive determination of cardiac output by the inert-gas-rebreathing method—comparison with cardiovascular magnetic resonance imaging. Cardiology 114(4):247–254. doi:10.​1159/​000232407 CrossRefPubMed
50.
Zurück zum Zitat Yancy C, Abraham WT (2003) Noninvasive hemodynamic monitoring in heart failure: utilization of impedance cardiography. Congest Heart Fail 9(5):241–250CrossRefPubMed Yancy C, Abraham WT (2003) Noninvasive hemodynamic monitoring in heart failure: utilization of impedance cardiography. Congest Heart Fail 9(5):241–250CrossRefPubMed
Metadaten
Titel
Biological variation of extracellular matrix biomarkers in patients with stable chronic heart failure
Publikationsdatum
04.08.2017
Erschienen in
Clinical Research in Cardiology / Ausgabe 12/2017
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-017-1147-5

Weitere Artikel der Ausgabe 12/2017

Clinical Research in Cardiology 12/2017 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.